We also applied the Srps on large‐scale dataset with anti‐PD‐1/PD‐L1/CTLA4 treatment and found that Srps performed certain accuracy to predict treatment response on eight of total 25 cohorts (AUC > 0.7), which demonstrated the potential utility of Srps in pan‐cancer immunotherapy response (Figure S1). This evidence concerns the gene CTLA4 and cancer.